End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
Bijal Shah(Boston College), William G. Wierda(University of Maryland, Baltimore), Martha Arellano(Memorial Sloan Kettering Cancer Center), Remus Vezan(National University of Misiones), William B. Donnellan(Sarah Cannon), Kristen Marie Carr-O'Dwyer(University of Rochester Medicine), John M. Pagel(University of Washington), Tong Shen(Qingdao University of Science and Technology), Olalekan O. Oluwole(Vanderbilt University), Maria R. Baer(University of Maryland, Baltimore), Lovely Goyal(Gilead Sciences (Australia)), Aaron C. Logan(University of California, San Francisco), Ryan D. Cassaday(University of Washington), Armin Ghobadi(Washington University in St. Louis), Yi Lin, Jae Hong Park(Memorial Sloan Kettering Cancer Center), Houston Holmes(Texas Oncology), Armen Mardiros, Michael Bishop(Peter MacCallum Cancer Centre), Rajul K. Jain(Amgen (United States))
Cited by 38
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k